Liminatus Pharma, Inc. Class A Common Stock (LIMN) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Liminatus Pharma, Inc. Class A Common Stock, with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Valuation | |||||
| P/E Ratio | -1.42x | -12.41x | -32.74x | -58.91x | 39.56x |
| P/B Ratio | -1.48x | -2.27x | -3.75x | 133.28x | 0.68x |
| P/S Ratio | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Profitability | |||||
| Gross Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| EBITDA Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Liquidity | |||||
| Current Ratio | 0.05x | 0.09x | 0.04x | 0.10x | 0.31x |
| Quick Ratio | 0.05x | 0.09x | 0.04x | 0.10x | 0.31x |
| Leverage | |||||
| Debt/Equity | -0.15x | -0.32x | -1.50x | 12.75x | 0.00x |
YoY = year-over-year change. Source: FMP..